The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Extended-Release Drugs Market Over The 2026–2030 Period?
The extended-release drugs market size has seen swift expansion in recent years. It is forecast to rise from $69.63 billion in 2025 to $77.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.9%. The factors contributing to this historic growth include the increasing prevalence of chronic diseases, a drive for patient-centric drug formulations, the inherent limitations of immediate-release drugs, an upward trend in healthcare expenditure, and improvements in pharmaceutical excipients.
The extended-release drugs market is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $126.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. This expansion during the forecast timeframe is attributable to several factors, including the advancement of precision medicine, wider acceptance of oral controlled-release formulations, the expansion of hospital and retail pharmacy networks, an increasing elderly demographic, and financial commitments towards innovative delivery technologies. Key developments expected during this period encompass tailored dosage regimens, sophisticated drug delivery systems, strategies to enhance patient adherence, new formulation technologies, and extended-release combination therapies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp
Which Major Factors Are Driving The Expansion Of The Extended-Release Drugs Market?
The rising occurrence of chronic health issues is expected to drive the growth of the extended-release drug market moving forward. Chronic conditions are characterized as health problems that last for a year or longer and necessitate ongoing medical care, restrict everyday activities, or both. Heart disease, cancer, obesity, and diabetes are some illustrative examples. Extended-release drug delivery systems are developed to maintain a relatively stable level of medication in the body over an extended period. This approach assists in sustaining a consistent therapeutic effect and avoids the variations in drug levels that can occur with immediate-release medications. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was predicted that by 2050, the count of individuals aged 50 years and older having at least one chronic illness will increase by 99.5%, reaching 142.66 million. Therefore, the expanding incidence of chronic conditions is propelling the expansion of the extended-release drug market.
How Is The Extended-Release Drugs Market Segmented Across Key Categories?
The extended-release drugs market covered in this report is segmented –
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems
Which Upcoming Trends Are Expected To Influence The Extended-Release Drugs Market?
Leading companies in the extended-release drugs market are developing innovative products, such as next-generation extended-release tablets, to enhance their product offerings and gain a competitive advantage. Extended-release tablets are a pharmaceutical formulation designed to gradually release their active ingredients over an extended period. For instance, in February 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for austedo XR (deutetrabenazine). Austedo XR is recommended for the treatment of adults with chorea and tardive dyskinesia related to Huntington disease, available in dosages of 6, 12, and 24 mg. With the approval of austedo XR, patients with tardive dyskinesia and Huntington disease chorea now have another efficient treatment option, allowing individuals to manage these disorders with medication administered once daily. The development of austedo XR, which provides a practical and efficient therapeutic alternative for those with certain movement disorders, signifies a significant leap in the management of these ailments.
Who Are The Dominant Players Shaping The Extended-Release Drugs Market Landscape?
Major companies operating in the extended-release drugs market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Watson Pharmaceuticals Inc.
Read the full extended-release drugs market report here:
https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report
Which Region Currently Holds The Largest Share Of The Extended-Release Drugs Market?
North America was the largest region in the extended-release drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Extended-Release Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp
Browse Through More Reports Similar to the Global Extended-Release Drugs Market 2026, By The Business Research Company
Extended Release Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report
Controlled Release Drug Delivery Market Report 2026
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model